# **AG490**

# Janus kinase 2 inhibitor

Catalog # tlrl-ag4

# For research use only

Version # 15K02-MM

# PRODUCT INFORMATION

#### **Content:**

• 10 mg AG490

## **Storage and stability:**

- AG490 is provided as a translucent film and shipped at room temperature. Store at -20 °C. Solid product is stable 1 year at -20 °C.
- Upon resuspension, AG490 should be aliquoted and stored at -20  $^{\circ}$ C. Avoid repeated freeze-thaw cycles. Resuspended product is stable for 6 months at -20  $^{\circ}$ C when properly stored.

## **Quality control:**

- Purity: ≥99% (UHPLC)
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

## DESCRIPTION

AG490 is a specific and potent inhibitor of the Janus kinase 2 protein (JAK2)<sup>1</sup>. JAK2 regulates the phosphorylation of JNK, primarily through PI3K. It has been established that JAK2 plays an important role in TLR-mediated biological responses, blocking TLR4-mediated responses to LPS<sup>2</sup> and TLR5-mediated responses to flagellin<sup>3</sup>. JAK2 is also involved in cytokine signaling, such as IL-2, IL-6 and IL-12.

## **CHEMICAL PROPERTIES**

**Synonym:** Tyrphostin B42 **Formula:** C17H14N2O3 **Molecular weight:** 294.3

Solubility: 50 mg/ml in DMSO and 5 mg/ml in ethanol

**Structure:** 

#### **METHODS**

## Preparation of stock solution (40 mM)

- 1. Add 850 µl DMSO to 10 mg AG490.
- 2. Vortex until complete solubilization. Prepare aliquots and store at -20 °C. Once AG490 is solubilized, dilutions can be prepared with aqueous buffers.

Working concentration: 20-50 μM for cell culture assays

# **PROTOCOLS** (For reference only)

#### Cell Culture Assav<sup>3</sup>

Cells: Bone marrow-derived macrophages

Working concentration:  $20~\mu M$ 

**Incubation time:** 1 h

Method: Western blotting to study STAT1 activation

# Cell Culture Assay

**Cells:** U266 human myeloma cell line **Working concentration:** 25-50 μM

**Incubation time:** 24 h

Method: Flow cytometry and apoptosis assays

#### Animal Study<sup>5</sup>

Animal model: NOD and BALB/c mice

Dose: 1 mg/mouse

Administration: Intraperitoneal injection (i.p.)

1. Levitzki A. 1990. Tyrphostins- potential antiprolierative agents and novel molecular tools. Biochem. Pharmacol. 40:913-918. 2. Kimura A et al. 2005. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. PNAS 102:17089-17094 3. Ha H et al. 2008. Stimulation by TLR5 Modulates Osteoclast Differentiation through STAT1/IFN-β1. J. Immuno. 180:1382-1389. 4. Catlett-Falcone R. et al., 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999 10(1):105-15. 5. Davoodi-Semiromi A. et al., 2012. The tyrphostin agent AG490 prevents and reverses Type 1 diabetes in NOD mice. PLoS One. 7(5):e36079.

# RELATED PRODUCTS

Product	Catalog Code
AZD1480	hibitor inh-ad14
CP-690550	tlrl-cp69
CP-690550	tiri-c
Ruxolitinib	hibitor tlrl-r

**TECHNICAL SUPPORT** 

InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com

